Saifullah Bullo1,2,3, Kalaivani Buskaran1, Rabia Baby4, Dena Dorniani5, Sharida Fakurazi1,6, Mohd Zobir Hussein7. 1. Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Malaysia. 2. Material Synthesis and Characterization Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, 43400, Serdang, Malaysia. 3. JCBI-School of Life Sciences, Henan University, Kaifeng, 475000, Henan, China. 4. Education Department, Sukkur IBA University, Sukkur, Sindh, 65200, Pakistan. 5. Chemistry Department, University of Sheffield, Dainton Building, Brook Hill, Sheffield, S3 7HF, UK. 6. Department of Human Anatomy, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, 43400 UPM, Serdang, Selangor Darul Ehsan, Malaysia. 7. Material Synthesis and Characterization Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, 43400, Serdang, Malaysia. mzobir@upm.edu.my.
Abstract
BACKGROUND: The chemotherapy of cancer has been complicated by poor bioavailability, adverse side effects, high dose requirement, drug resistance and low therapeutic indices. Cancer cells have different ways to inhibit the chemotherapeutic drugs, use of dual/multiple anticancer agents may be achieve better therapeutic effects in particular for drug resistant tumors. Designing a biocompatible delivery system, dual or multiple drugs could addressing these chemotherapy drawbacks and it is the focus of many current biomedical research. METHODS: In the present study, graphene oxide-polyethylene glycol (GOPEG) nanocarrier is designed and loaded with two anticancer drugs; Protocatechuic acid (PCA) and Chlorogenic acid (CA). The designed anticancer nanocomposite was further coated with folic acid to target the cancer cells, as their surface membranes are overexpressed with folate receptors. RESULTS: The particle size distribution of the designed nanocomposite was found to be narrow, 9-40 nm. The release profiles of the loaded drugs; PCA and CA was conducted in human body simulated PBS solutions of pH 7.4 (blood pH) and pH 4.8 (intracellular lysosomal pH). Anticancer properties were evaluated against cancerous cells i.e. liver cancer, HEPG2 and human colon cancer, HT-29 cells. The cytocompatbility was assessed on normal 3T3 fibroblasts cells. CONCLUSION: The size of the final designed anticancer nanocomposite formulation, GOPEG-PCACA-FA was found to be distributed at 9-40 nm with a median of 8 nm. The in vitro release of the drugs PCA and CA was found to be of sustained manner which took more than 100 h for the release. Furthermore, the designed formulation was biocompatible with normal 3T3 cells and showed strong anticancer activity against liver and colon cancer cells.
BACKGROUND: The chemotherapy of cancer has been complicated by poor bioavailability, adverse side effects, high dose requirement, drug resistance and low therapeutic indices. Cancer cells have different ways to inhibit the chemotherapeutic drugs, use of dual/multiple anticancer agents may be achieve better therapeutic effects in particular for drug resistant tumors. Designing a biocompatible delivery system, dual or multiple drugs could addressing these chemotherapy drawbacks and it is the focus of many current biomedical research. METHODS: In the present study, graphene oxide-polyethylene glycol (GOPEG) nanocarrier is designed and loaded with two anticancer drugs; Protocatechuic acid (PCA) and Chlorogenic acid (CA). The designed anticancer nanocomposite was further coated with folic acid to target the cancer cells, as their surface membranes are overexpressed with folate receptors. RESULTS: The particle size distribution of the designed nanocomposite was found to be narrow, 9-40 nm. The release profiles of the loaded drugs; PCA and CA was conducted in human body simulated PBS solutions of pH 7.4 (blood pH) and pH 4.8 (intracellular lysosomal pH). Anticancer properties were evaluated against cancerous cells i.e. liver cancer, HEPG2 and humancolon cancer, HT-29 cells. The cytocompatbility was assessed on normal 3T3 fibroblasts cells. CONCLUSION: The size of the final designed anticancer nanocomposite formulation, GOPEG-PCACA-FA was found to be distributed at 9-40 nm with a median of 8 nm. The in vitro release of the drugs PCA and CA was found to be of sustained manner which took more than 100 h for the release. Furthermore, the designed formulation was biocompatible with normal 3T3 cells and showed strong anticancer activity against liver and colon cancer cells.
Entities:
Keywords:
anticancer; chlorogenic acid (CA); drug delivery; graphene oxide; nanobiomaterial; polyethylene glycol (PEG) and Protocatechuic acid (PCA)
Authors: Tais Monteiro Magne; Thamires de Oliveira Vieira; Luciana Magalhães Rebelo Alencar; Francisco Franciné Maia Junior; Sara Gemini-Piperni; Samuel V Carneiro; Lillian M U D Fechine; Rafael M Freire; Kirill Golokhvast; Pierangelo Metrangolo; Pierre B A Fechine; Ralph Santos-Oliveira Journal: J Nanostructure Chem Date: 2021-09-06
Authors: Noha Mokhtar Abd-El-Aziz; Mohamed S Hifnawy; Ahmed A El-Ashmawy; Rehab A Lotfy; Inas Y Younis Journal: Sci Rep Date: 2022-05-25 Impact factor: 4.996
Authors: Karolina Ławkowska; Marta Pokrywczyńska; Krzysztof Koper; Luis Alex Kluth; Tomasz Drewa; Jan Adamowicz Journal: Int J Mol Sci Date: 2021-12-21 Impact factor: 5.923